YBX1 and chronic myelogenous leukemia, BCR-ABL1 positive: It modulates the stability of target transcripts by recognizing the m5C modification.[7a] Previous studies have demonstrated the oncogenic function of YBX1 as an RNA‐binding protein in tumorigenesis and cancer metastasis such as hepatocellular carcinoma (HCC),[8] colorectal cancer,[9] Chronic myeloid leukemia[10] and clear cell renal cell carcinoma.[11] Recently, increasing evidence has demonstrated that YBX1 functions as an m5C reader in bladder,[7a] breast,[12] and gynecologic cancers.[13] However, the role of YBX1 in the progression of ESCC remains unclear.